

Original Article

A STUDY ON CLINICAL FEATURES AND COST INCURRED BY DENGUE SYNDROME PATIENTS ADMITTED TO A TERTIARY CARE HOSPITAL

Sathish Chandra MR¹, Ashwath Narayana DH², Manjunath M³

Financial Support: None declared

Conflict of interest: None declared

Copy right: The Journal retains the copyrights of this article. However, reproduction of this article in the part or total in any form is permissible with due acknowledgement of the source.

How to cite this article:

Chandra S, Ashwath Narayana DH, Manjunath M. A Study on Clinical Features and Cost Incurred by Dengue Syndrome Patients Admitted to a Tertiary Care Hospital. Natl J Community Med 2014; 5(3):293-5.

Author's Affiliation:

¹Assistant Professor, Department of Community Medicine, BGS Global Institute of Medical Sciences, Bangalore;
²Professor & Head, Department of Community Medicine, Kempegowda Institute of Medical Sciences, Bangalore;
³Intern, Kempegowda Institute of Medical Sciences, Bangalore.

Correspondence:

Dr. Sathish Chandra M.R
Email: sathi.medico@yahoo.co.in, sathishchandramr@gmail.com

Date of Submission: 28-02-14

Date of Acceptance: 24-05-14

Date of Publication: 30-9-14

ABSTRACT

Introduction: Dengue infections are a significant cause of morbidity and mortality which leads to adverse economic effects in many developing tropical countries. The present study allows in better understanding of the clinical presentations and also helps in describing economic burden of the same. Objective of the study was to describe the clinical features, case fatality and cost incurred of dengue syndrome admitted to tertiary care hospital.

Methodology: It was descriptive study done on patients admitted with clinical signs and symptoms of dengue during 2010-11 at KIMS Hospital & Research Center, Bangalore. The cost incurred by the patients in respect to hospital charges, laboratory investigations and drugs provided will be analyzed from the entries from the case records. These patients will be followed up through telephone contact provided in the case records.

Results: Out of 325 cases who had clinical signs and symptoms of dengue, 200 were found positive NS1 Ag/IgM/IgG for dengue. 62% among them were males. 35.5% were in the age group of 21-30 years. Majority (92.5%) had Classical Dengue followed by DHF (7%) and DSS (0.5%). Most common clinical symptom was fever (94%) followed by vomiting (45.5%) and abdominal pain (33%). Hemoglobin was >12gm% in 73.4% of cases. Case fatality was found to be 1.5%. Direct median cost was found to be Rs.12,611/- and indirect median cost was Rs.3109/-

Conclusion: Professionals and public should be made aware of common clinical manifestations of dengue syndrome for early reporting and seeking prompt treatment there by reducing the case fatality rate and the economic loss to the patients and country at large.

Keywords: dengue syndrome, direct cost, indirect cost

INTRODUCTION

Dengue is a serious mosquito-borne viral disease which in recent years has become a major international public health concern. It is the most serious viral haemorrhagic fever in the world with an annual incidence of 100 million cases per year.¹Dengue viruses cause symptomatic infections or asymptomatic seroconversion. It has a wide clinical spectrum that includes both severe and non-severe clinical manifestations.²

NS1 antigen is highly conserved glycoprotein that is present at high concentrations in the sera of dengue-infected patients during the early clinical phase of the disease. NS1 antigen is found from the first day and up to 9 days after onset of fever in blood sample of primary or secondary dengue infected patients.⁵ Posi-

tive serology (anti dengue antibody) is the mainstay in the diagnosis of DF. Usually IgM does not become detectable until 5- 10 days^{3,4} after the onset of illness in cases of primary dengue infection and until 4-5 days after onset of illness in secondary infections. In primary infections, IgG appear from 14th day and persist for life. Secondary infections show that IgG rise 1-2 days after the onset of symptoms and induce IgM response after 20 days of infection.⁵

The need of this study is to know varied clinical presentations, estimating the economic burden due to the same in India where only few studies are available. The study may help in diagnosis the disease early and providing effective management of the patient with dengue infection and hence reducing the mortality rate. Objective of the study was to describe the clinical

features, case fatality and cost incurred of dengue syndrome admitted to tertiary care hospital.

METHODOLOGY

It was a descriptive study done on patients admitted with signs and symptoms of dengue syndrome in KIMS Hospital & Research Center, Bangalore during 2010-11.

Out of 325 cases admitted with clinical signs and symptoms suggestive of dengue syndrome 200 (61.5%) cases were found positive for NS1 antigen\IgM\IgG positivity for dengue using SD BioLine kit. The medical records were perused for collecting data about these cases using a pre-designed proforma. Data was analyzed for the clinical presentations, direct cost incurred in respect to hospital charges and laboratory investigations. Cost of the drugs provided was analyzed from the entries from the case records. Information regarding the indirect cost (loss of daily wages of patients & attendants incurred) was collected through telephonic contact.

RESULTS

Out of 325 suspect case of dengue 200 (61.5%) cases were found positive for NS1 antigen\ IgM\ IgG. Among 200 positive cases, males were 124 (62%) and females 76 (38%). 35.5% of the cases were in the age group of 21-30 years followed by 20.5% in 11-20 years. Median age group was 26 years; Range was 1-70 years (Table-1).

Majority 92.5% of cases presented as Classical dengue, 7% with dengue hemorrhagic fever and 0.5% with dengue shock syndrome (Table -3). 94% of cases had fever, 45.5% had vomiting and 33% had abdominal pain. 56.6% had moderate fever, associated chills and rigors in 51.3% of cases (Table- 2). Hemorrhagic manifestations were seen in about 4.5% of cases of which majority presented with haematemesis followed by epistaxis. Rashes were seen in 2% and joint pain in 13% of cases. Hepatomegaly was seen in 19%, splenomegaly in 10.5% and Pleural effusion in 5% of cases.

Hemoglobin level of > 12gm% was found in 73.4%, 9-12 gm% in 23.4%, 6-9gm% in 2.1% and < 6 gm% in 1.1% of cases. Platelet count of < 20,000 was found in 21.5% of cases, 20-50 thousand in 39.5% , 50,000 to 1.5 lakh in 36% of cases and >1.5 lakh was found in 3% of cases. Increased levels of Urea and Creatinine were found in 7.4% of cases.

Majority (58%) of cases were IgM & IgG positive, 16% were positive for IgG and 8% were positive for IgM, IgG& Ag (Table 5).

Transfusion was done in about 96 (48%) cases of which 95 (99%) received platelet transfusion (Average 3.24 units). 6 (6.3%) cases received fresh frozen plasma and 1 (1%) received whole blood transfusion in addition to platelet transfusion.

Table 1: Age and sex wise distribution of cases

Age	Males (%)	Females (%)	Total
1-10	9 (4.50)	7 (3.50)	16 (8.00)
11-20	25 (12.50)	16 (8.00)	41 (20.50)
21-30	52 (26.00)	19 (9.50)	71 (35.50)
31-40	22 (11.00)	14 (7.00)	36 (18.00)
41-50	9 (4.50)	14 (7.00)	23 (11.50)
51-60	5 (2.50)	6 (3.00)	11 (5.50)
61-70	2 (1.00)	-	2 (1.00)
Total	124 (62.00)	76 (38.00)	200 (100.00)

Table 2: Presenting complaints among patients

Presenting Complaints	Number (%)
Fever	188 (94)
Myalgia	39 (19.5)
Hemorrhagic manifestations	9 (4.5)
Vomiting	91 (45.5)
Abdominal pain	66 (33)
Headache	53 (26.5)
Arthralgia	11 (5.5)
Diarrhea	21 (10.5)
Others	32 (16)

Table 3: Presenting pattern of dengue cases

Dengue presentations	Male	Female	Total
Classical Dengue	114 (57)	71 (35.5)	185 (92.5)
Dengue Hemorrhagic Fever	9 (4.5)	5 (2.5)	14 (7.0)
Dengue Shock Syndrome	1 (0.5)	0	1 (0.5)

Figure in parenthesis indicate percentage

Table 4: Average cost incurred among dengue syndrome patients

Type of cost	Inclusion	Cost (INR)
Direct	Transportation of patient, diagnostic & laboratory investigations, medications, hospitalization & food	12,611.00
Indirect	Loss of wages of patient and attendants	3,109.00
Other	Treating co-morbid conditions	2,275.00
Total Cost		17,995.00

Table 5: Laboratory confirmation of cases NS1 Ag/ IgM/ IgG positivity

Antigen/ antibody	Number (%)
IgM	7 (3.5%)
IgG	33 (16.5%)
Ag	15 (7.5%)
IgM/IgG/ Ag	15 (7.5%)
IgM/IgG	116 (58%)
IgM/ Ag	11 (5.5%)
Ag/ IgG	3 (1.5%)

Case fatality rate (% of deaths among dengue syndrome patients) was found to be 1.5%. Previous history of dengue infection was seen in 4% of cases.

Cost incurred which includes direct median cost (transporting patient to the hospital, diagnostic testing and lab investigations, medications, hospitalization, food) was found to be Rs. 12,611=00. The indirect median cost (loss of wages of patient & attendants) was

found to be an average of Rs.3,109=00. The hidden cost (out of pocket expenses) was Rs.50=00. The cost of treatment of other co-morbid conditions was found to be Rs.2,275=00. The total cost of treating dengue syndrome was approximately Rs.17,995=00.(Table- 4)

DISCUSSION

In the present study, it was found that males were commonly affected and most common age group was between 21-30 yrs of age which is similar to the findings by Deepinder Kaur Chhina^{et al} which was 21-30yrs.⁶

In the present study, the most common presenting symptoms was fever followed by vomiting and abdominal pain which is similar to study done by Kumar A et al showed fever in 99.2% followed by myalgia (64.6%), vomiting (47.6%), headache (47.6%) and abdominal pain (37.5%).⁷

In the present study, the most common bleeding manifestation was hematemesis and epistaxis similar to findings done by Aggarwal A et al⁸ and Pushpa V et al⁹ whereas during 2006 outbreak of dengue in North India, malena (50%) and hematemesis (38%) were the common bleeding manifestation.¹⁰

In the present study rashes were seen in 2% whereas study done by Ahmed FU et al¹¹ where rashes were found in 12% of children.

In the present study, Sera positivity rate of 58% for IgM and IgG and Hemoglobin > 12gm% was seen in 73.4% of cases which may be due to haemo-concentration.

In the present study, Case fatality rate was found to be 1.5% which is similar to findings of Ahmed et al¹¹ and Itha S et al.¹²

There is lack of data in our country on the cost incurred by dengue syndrome patients. However, in the present study, the total cost of treating dengue syndrome was approximately Rs. Rs.17,995=00 per patient was significantly higher for vast majority of patients who cannot afford to pay.

CONCLUSION

The sero positivity for dengue was 61.5% with NS1 antigen\ IgM\ IgG. Males were commonly affected and 35.5% of the cases were in the age group of 21-30 years. Median age group was 26 years. Majority 92.5% of cases presented as Classical dengue, 7% with dengue hemorrhagic fever and 0.5% with dengue shock syndrome.

The estimated direct median cost was Rs. 12,611=00, indirect median cost was Rs.3,109=00, hidden cost was Rs.50=00 and cost of treating other co-morbid conditions was Rs.2,275=00. The total cost of treating dengue syndrome cases in tertiary care hospital was approximately Rs.17,995=00 per patient.

Professionals and public should be made aware of common clinical manifestations of dengue syndrome for early reporting and seeking prompt treatment there by reducing the case fatality rate and the economic loss to the patients and country at large.

Acknowledgement: Authors like to acknowledge Indian Council Medical Research for sponsoring the study. (STS- REFERENCE ID: 2011-03503)

REFERENCES

1. Price DD, Wilson SR. Dengue Fever. Available at:<http://emedicine.medscaDe.com/article/78>. Accessed on 26th June 2012.
2. Rigau-Pérez JG, Clark GG, Gubler DJ, Reiter P, Sanders EJ, Vorndam AV. Dengue and dengue haemorrhagic fever. *Lancet*, 1998, 352:971-77.
3. Rahman M, Rahman K, Siddique AK et al. First outbreak of dengue haemorrhagic fever, Bangladesh. *Emerg Infect Dis* 2002; 8(7): 738-40.
4. Bhamarapravti N. Pathology of dengue haemorrhagic fever. In: Thongcharoen P (ed) *Dengue/dengue haemorrhagic fever*. WHO, Geneva 1993; 72-3.
5. Pryor MJ, Wright PJ. The effects of site-directed mutagenesis on the dimerization and secretion of the NS1 protein specified by dengue virus. *Virology* 1993; 194:168-80.
6. Deepinder Kaur Chhina, Omesh Goyal, Prerna Goyal, Raj Kumar. Haemorrhagic manifestations of dengue fever and their management in a tertiary care hospital in north India: *Indian J Med Res* 129; 2009:718-20.
7. Kumar A, Rao CR, Pandit V, Shetty S, Bammigatti C, Samarasinghe CM. Clinical manifestations and trend of dengue cases admitted in a tertiary care hospital, Udipi district, Karnataka. *Indian J Community Med* 2010;35:386-90.
8. Aggarwal A, Chandra J, Aneja S, Patwari AK, Dutta AK. An epidemic of dengue hemorrhagic fever and dengue shock syndrome in children in Delhi. *Indian Pediatr* 1998; 35: 727-732.
9. Pushpa V, Venkatesikal M, Mohan S, Cherian T, John TJ, Ponnuraj EM. An epidemic of dengue haemorrhagic fever/dengue shock syndrome in tropical India. *Ann Trop Pediatr* 1998; 18: 289-293.
10. Shah I, Deshpande GC, Tardeja PN. Outbreak of dengue in Mumbai and Predictive Markers of dengue Shock Syndrome. *J Trop Pediatr* 2004; 50:301-305.
11. Ahmed FU, Mahmood BC, Sharma JD, Hoque SM, Zaman R, Hasan MS. Dengue and Dengue Haemorrhagic Fever in Children During the 2000 Outbreak in Chittagong, Bangladesh. *Dengue Bulletin* 2001; 25: 33-39.
12. Itha S, Kashyap R, Krishnani N, Sarawat VA, Choudhuri G, Aggarwal R. Profile of liver involvement in dengue virus infection. *Nat Med J India* 2005;18:17-30.